Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00480753 · ClinicalTrials.gov registry record · Phase 2
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
A Phase 2 study, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00480753 is a Phase 2 study that has completed, run by MediQuest Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT00480753, a Phase 2 study, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon. Patient fingers will be monitored for changes in blood flow and skin temperature. Symptoms of pain, tingling and numbness will also be monitored.
Interventions
- DRUG Nitroglycerin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00480753
The ClinicalTrials.gov registry entry for NCT00480753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediQuest Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nitroglycerin is the first listed.
NCT00480753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00480753 about?
NCT00480753 is a clinical study titled "Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon". The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon. Patient fingers will be monitored for changes in blood flow and skin temperature. Symptoms of pain, tingling and numbness will also ...
What is the current status of trial NCT00480753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00480753?
The interventions under investigation include: Nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00480753?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.